Ameriprise
CCCC icon

Ameriprise’s C4 Therapeutics CCCC Stock Holding History

Ameriprise’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,620
Closed -$66.2K – 4092
2024
Q3 		$66.2K Buy
+11,620
New +$69.9K ﹤0.01% 3869
2023
Q4 		– Sell
-69,486
Closed -$129K – 3907
2023
Q3 		$129K Sell
69,486
-110
-0.2% -$336 ﹤0.01% 3758
2023
Q2 		$191K Sell
69,596
-10,539
-13% -$33.9K ﹤0.01% 3739
2023
Q1 		$252K Buy
80,135
+41,487
+107% +$244K ﹤0.01% 3658
2022
Q4 		$228K Sell
38,648
-7,810
-17% -$64.8K ﹤0.01% 3673
2022
Q3 		$407K Buy
+46,458
New +$482K ﹤0.01% 3465

Other funds holding CCCC

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise's CCCC Position: Q4 2024 in Review

Ameriprise sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 11,620 shares — an estimated $66.2K sold.

Ameriprise first reported a position in CCCC in Q3 2022 and held it in 6 quarters. The position peaked at $407K in Q3 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

  • Ameriprise reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Ameriprise sold 11,620 C4 Therapeutics shares in Q4 2024, an estimated $66.2K.
  • Ameriprise first reported a position in C4 Therapeutics in Q3 2022 and held it in 6 quarters.
  • Ameriprise's C4 Therapeutics position peaked at $407K in Q3 2022.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on Ameriprise's 13F filing for Q4 2024, filed 14 Feb 2025.